
CBE ID

0610

Title

Heart Failure - Use of ACE Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) Therapy

Project

National Voluntary Consensus Standards For Clinically Enriched Administrative Data

Endorsement Status

Endorsement Removed

Is Under Review

No

Previous Endorsement Cycle

Full Year 2009

Removal Date

Mon, 02/03/2014 - 19:00

Initial Endorsement

Thu, 12/03/2009 - 19:00

Steward

ActiveHealth Management

1.0 New or Maintenance

Maintenance

1.1 Measure Structure

Single Measure

1.3 Electronic Clinical Quality Measure (eCQM)

No

1.6 Measure Description

The percentage of patients aged 18 and older with Heart Failure who are on an ACEI or ARB

1.7 Measure Type

Process

1.8 Level of Analysis

Clinician: Group/Practice, Clinician: Individual, Facility, Health Plan, Integrated Delivery System, Other, Population: Community, County or City, Population: Regional and State

1.9 Care Setting

Home Care, Inpatient/Hospital, Outpatient Services

1.14 Numerator

Patients with a current fill for an ACEI or ARB

1.15 Denominator

All patients, aged 18 years and older, with a diagnosis of heart failure

1.20 Types of Data Sources

Claims Data, Electronic Health Data, Electronic Health Records: Electronic Health Records, Instrument-Based Data, Other

6.1.2 Current or Planned Use(s)

Public Reporting, Quality Improvement (Internal to the specific organization)

6.1.3 Current Use(s)

Public Reporting, Quality Improvement (Internal to the specific organization)

Exclusions

Contraindications to an ACEI or ARB, including:

- Hyperpotassemia
- Hypertrophic cardiomyopathy
- Aortic stenosis
- Hypotension
- Pregnancy
- Chronic kidney disease stage 3 and 4
- Chronic kidney disease stage 5 in the absence of dialysis
- Hydralazine after prior ACE-I/ARB use
- 20% increase in creatinine
- Aliskerin
- Multiple myeloma
- Patient data indicating that the member is planning pregnancy

Additional denominator exclusions:

- Heart transplant
- Pulmonary hypertension treatment
- Valve surgery
- Patient or provider feedback indicating allergy, intolerance or contraindication

General exclusions:

- Evidence of metastatic disease or active treatment of malignancy (chemotherapy or radiation therapy) in the last 6 months;

- Patients who have been in a skilled nursing facility in the last 3 months

Planned Use

Public Reporting, Quality Improvement (Internal to the specific organization)

Risk Adjustment

No risk adjustment or risk stratification

Steward Organization

ActiveHealth Management

Steward POC email

mvemireddy@activehealth.net